Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study.

导出 OA

翻译打印收藏纠错

第一作者： Luis,Secanella

第一单位： Digestive and General Surgery Department, Bellvitge University Hospital, L'Hospitalet DE Llobregat, Barcelona, Spain.;Research Group of Hepato-Biliary and Pancreatic Diseases, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, University of Barcelona, L'Hospitalet DE Llobregat, Barcelona, Spain.

作者： Luis,Secanella ^[1] ; Juli,Busquets ^[2] ; Núria,Peláez ^[1] ; María,Sorribas ^[1] ; Berta,Laquente ^[3] ; Sandra,Ruiz ^[4] ; Thiago,Carnaval ^[5] ; Sebastián,Videla ^[6] ; Juan,Fabregat ^[2]

作者单位： Digestive and General Surgery Department, Bellvitge University Hospital, L'Hospitalet DE Llobregat, Barcelona, Spain.;Research Group of Hepato-Biliary and Pancreatic Diseases, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, University of Barcelona, L'Hospitalet DE Llobregat, Barcelona, Spain. ^[1] Digestive and General Surgery Department, Bellvitge University Hospital, L'Hospitalet DE Llobregat, Barcelona, Spain.;Research Group of Hepato-Biliary and Pancreatic Diseases, Institut d'Investigació Biomèdica de Bellvitge - IDIBELL, University of Barcelona, L'Hospitalet DE Llobregat, Barcelona, Spain.;Departament de Ciències Clíniques, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), C. Casanova, Barcelona, Spain. ^[2] Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, L'Hospitalet DE Llobregat, Barcelona, Spain. ^[3] Radiology Department, Bellvitge University Hospital, L'Hospitalet DE Llobregat, Barcelona, Spain. ^[4] Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, IDIBELL, University of Barcelona, L'Hospitalet DE Llobregat, Barcelona, Spain. ^[5] Pharmacology Unit, Department of Pathology and Experimental Therapeutics, School of Medicine and Health Sciences, IDIBELL, University of Barcelona, L'Hospitalet DE Llobregat, Barcelona, Spain.;Clinical Research Support Unit (HUB·IDIBELL), Clinical Pharmacology Department, Bellvitge University Hospital, L´Hospitalet DE Llobregat, Barcelona, Spain. ^[6]

主题词人类(Humans);肿瘤辅助疗法(Neoadjuvant Therapy);回顾性研究(Retrospective Studies);胰腺肿瘤(Pancreatic Neoplasms)

DOI 10.1097/MD.0000000000032126

PMID 36482640

发布时间 2022-12-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交